|Articles|October 18, 2022

Evaluating Biopharma

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Trending on BioPharm International

Evaluating Biopharma

Newsletter

Related Content

mRNA development with quantitative expression analysis

Low-ng/mL quantitation of glucagon-like peptide-1 (GLP-1) analog in rat plasma

Sensitive LC-MRMHR approach for cyclic peptide quantitation in human plasma

Dos and Don’ts of oligonucleotide analysis

Low-pg/mL quantification of TL 13-112, a proteolysistargeting chimera (PROTAC) in rat plasma

Trending on BioPharm International

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

Roche Drives Industry Shift With Three-Year Lymphoma Survival Data

How Mitigation and Maintenance Protect Against Future Risk

FAQ: Milestones You May Have Missed in the 2025 Biopharma Pipeline

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline